SCHEMBL550087

SCHEMBL550087

O=C(Cl)c1cc(Cl)ncn1

nearest known ligand 0.39

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KMO O15229 15/20 0.39
SIRT6 Q8N6T7 1/20 0.38
NAPRT Q6XQN6 1/20 0.33
GRM4 Q14833 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272230 0.85 KMO (0.39) KMOSIRT6LMNA
SCHEMBL28242027 0.84 KMO (0.40) KMOSIRT6GRM4MEN1KMT2A
SCHEMBL3034461 0.82 KMO (0.56) KMO
SCHEMBL882676 0.80 KMO (0.38) KMO
SCHEMBL31196442 0.80 SIRT6 (0.50) KMOSIRT6LMNA
SCHEMBL24713180 0.80 KMO (0.36) KMOSIRT6
Hydrochloric Acid SCHEMBL550088 0.80 KMO (0.55) KMO
SCHEMBL2774810 0.80 KMO (0.38) KMOSIRT6GRM4MEN1KMT2A
SCHEMBL1743935 0.80 KMO (0.38) KMOSIRT6GRM4MEN1KMT2A
SCHEMBL2774815 0.80 SIRT6 (0.50) KMOSIRT6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612386-B2 Heteroaryl-triazole compounds as pesticides BAYER AKTIENGESELLSCHAFT (DE) 2026-04-28 US disclosed
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 US disclosed
US-12522584-B2 3,4-dihydroisoquinoline compound and use thereof CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) 2026-01-13 US disclosed
CN-115996639-B Novel heteroaryl-triazole compounds as pesticides 拜耳公司 2025-06-13 CN disclosed
CN-119504710-A PROTACs compound for targeted degradation of PRMT5 and application thereof 昆明医科大学 2025-02-25 CN disclosed
US-20250051307-A1 SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO.,LTD (CN) 2025-02-13 US disclosed
EP-4446317-A1 SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2024-10-16 EP disclosed
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-10-10 US disclosed
CN-113767092-B Di-heterocyclic carbonyl substituted dihydropyrazoles, their preparation and their use in medicine 劲方医药科技(上海)有限公司 2024-07-16 CN disclosed
EP-4146643-B1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AG (DE) 2024-05-29 EP disclosed
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed
CN-1146542-C Benzamide derivatives and their use as cytokine inhibitors 2004-04-21 CN disclosed
EP-1115707-B1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2003-11-12 EP disclosed
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed
US-6455520-B1 TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS ASTRA ZENECA AB (SE) 2002-09-24 US disclosed
CN-1319092-A Benzamide derivatives and their use as cytokine inhibitors ASTRAZENECA AB (SE) 2001-10-24 CN disclosed
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 EP disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 KMO 1505/4885SIRT6 1335/4885NAPRT 2166/4885
US-12612386-B2 Heteroaryl-triazole compounds as pesticides CBR3, CYCS, HCN1 KMO 1120/4885SIRT6 2560/4885NAPRT 4742/4885
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN KMO 3770/4885SIRT6 1244/4885NAPRT 631/4885
US-20090012091-A1 Oximide derivatives and their therapeutical application CYP11B2, NOS2, HMOX2 KMO 635/4885SIRT6 900/4885NAPRT 2006/4885
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof PRMT5, PRMT1, PRMT6 KMO 951/4885SIRT6 521/4885NAPRT 3311/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 KMO 813/4885SIRT6 2238/4885NAPRT 700/4885
US-20250051307-A1 SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF SLC26A3, SLC38A7, SLC10A1 KMO 2124/4885SIRT6 1783/4885NAPRT 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.